Shares of Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and opera ...

TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...

The Trump administration has pledged to curb rising obesity with school meal reforms and artificial dye bans, though the ...

About 2% of U.S. adults use GLP-1 drugs, but results vary. Diet, exercise, and mental health remain key to long-term success.

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...